Researchers at Kazan Federal University in Russia are in the process of testing biodegradable plant-based implants that might one day replace artificial prostheses, eliminating the need for repeat surgeries as a patient’s vasculature evolves.

Two days of debate over the safety of paclitaxel-coated and -eluting devices have culminated in a nonbinding recommendation by the FDA to continue sales of such devices for PAD patients, though the agency is also urging regulators to push for better long-term clinical data than is currently available.

The Cardiovascular Research Foundation is partnering with VEITHsymposium, one of the largest annual meetings in vascular medicine, to enhance conference material at both VEITHsymposium and the CRF’s yearly Transcatheter Cardiovascular Therapeutics conference, the groups announced June 20.

Incident coronary heart disease might be an early indicator of accelerated cognitive decline, according to work published ahead of print in the Journal of the American College of Cardiology.

A novel robotic catheter could simplify valve procedures while allowing cardiac surgeons to complete multiple interventions within the same time frame, according to research presented at TVT 2019 in Chicago.

Researchers at the University of Washington are hoping to catch out-of-hospital cardiac arrests early with an algorithm that, when integrated with smart speakers like the Google Home or Amazon Alexa, can monitor people for audible cardiac arrest symptoms while they sleep.

One in five Americans are able to recognize the symptoms of heart failure, according to a new survey from Abbott—a troublesome finding considering the same research puts the average individual just four degrees of separation from HF.

Online pharmacy Valisure on June 13 issued a letter to the FDA after in-house testing revealed dangerously elevated levels of N,N-Dimethylformamide (DMF) in certain lots of valsartan, an angiotensin II receptor blocker (ARB) commonly used to treat hypertension and heart failure.